Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
Form Type:
Zero Holdings:
Publication Time:
2016-06-15 17:00:20
Reporting Period:
Filing Date:
Accepted Time:
2016-06-15 17:00:20
SEC Url:
Form 4 Filing
Cik Name Symbol Sector (SIC) IRS No
1583648 Pieris Pharmaceuticals Inc. PIRS Services-Commercial Physical & Biological Research (8731) 300784346
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1650991 Louis Matis C/o Pieris Pharmaceuticals, Inc.
255 State Street, 9Th Floor
Boston MA 02109
Svp, Chief Development Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2016-06-13 2,085 $1.68 2,085 No 4 P Direct
Common Stock Acquisiton 2016-06-14 7,915 $1.71 10,000 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 4 P Direct
  1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.67 to $1.72, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges sent forth in this footnote.